China
· Delayed Price · Currency is CNY Hunan Jiudian Pharmaceutical Statistics
Total Valuation
Hunan Jiudian Pharmaceutical has a market cap or net worth of CNY 11.55 billion. The enterprise value is 11.30 billion.
| Market Cap | 11.55B |
| Enterprise Value | 11.30B |
Important Dates
The next estimated earnings date is Thursday, October 24, 2024.
| Earnings Date | Oct 24, 2024 |
| Ex-Dividend Date | May 24, 2024 |
Share Statistics
Hunan Jiudian Pharmaceutical has 489.63 million shares outstanding. The number of shares has increased by 2.78% in one year.
| Shares Outstanding | 489.63M |
| Shares Change (YoY) | +2.78% |
| Shares Change (QoQ) | -2.95% |
| Owned by Insiders (%) | 48.09% |
| Owned by Institutions (%) | 23.07% |
| Float | 249.38M |
Valuation Ratios
The trailing PE ratio is 24.97 and the forward PE ratio is 22.25.
| PE Ratio | 24.97 |
| Forward PE | 22.25 |
| PS Ratio | 4.00 |
| PB Ratio | 5.27 |
| P/FCF Ratio | 40.38 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.18, with an EV/FCF ratio of 39.53.
| EV / Earnings | 24.85 |
| EV / Sales | 3.98 |
| EV / EBITDA | 21.18 |
| EV / EBIT | 24.89 |
| EV / FCF | 39.53 |
Financial Position
The company has a current ratio of 3.99, with a Debt / Equity ratio of 0.19.
| Current Ratio | 3.99 |
| Quick Ratio | 3.07 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.76 |
| Debt / FCF | 1.42 |
| Interest Coverage | 23.49 |
Financial Efficiency
Return on equity (ROE) is 23.45% and return on invested capital (ROIC) is 12.22%.
| Return on Equity (ROE) | 23.45% |
| Return on Assets (ROA) | 10.24% |
| Return on Capital (ROIC) | 12.22% |
| Revenue Per Employee | 1.50M |
| Profits Per Employee | 240,234 |
| Employee Count | 1,893 |
| Asset Turnover | 1.03 |
| Inventory Turnover | 2.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +38.66% in the last 52 weeks. The beta is 0.50, so Hunan Jiudian Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | +38.66% |
| 50-Day Moving Average | 22.04 |
| 200-Day Moving Average | 24.36 |
| Relative Strength Index (RSI) | 57.98 |
| Average Volume (20 Days) | 8,789,013 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Hunan Jiudian Pharmaceutical had revenue of CNY 2.84 billion and earned 454.76 million in profits. Earnings per share was 0.94.
| Revenue | 2.84B |
| Gross Profit | 2.12B |
| Operating Income | 453.98M |
| Pretax Income | 496.46M |
| Net Income | 454.76M |
| EBITDA | 533.44M |
| EBIT | 453.98M |
| Earnings Per Share (EPS) | 0.94 |
Balance Sheet
The company has 650.36 million in cash and 406.27 million in debt, giving a net cash position of 244.09 million or 0.50 per share.
| Cash & Cash Equivalents | 650.36M |
| Total Debt | 406.27M |
| Net Cash | 244.09M |
| Net Cash Per Share | 0.50 |
| Equity (Book Value) | 2.18B |
| Book Value Per Share | 4.48 |
| Working Capital | 1.13B |
Cash Flow
In the last 12 months, operating cash flow was 651.73 million and capital expenditures -365.82 million, giving a free cash flow of 285.91 million.
| Operating Cash Flow | 651.73M |
| Capital Expenditures | -365.82M |
| Free Cash Flow | 285.91M |
| FCF Per Share | 0.58 |
Margins
Gross margin is 74.70%, with operating and profit margins of 15.98% and 16.01%.
| Gross Margin | 74.70% |
| Operating Margin | 15.98% |
| Pretax Margin | 17.47% |
| Profit Margin | 16.01% |
| EBITDA Margin | 18.78% |
| EBIT Margin | 15.98% |
| FCF Margin | 10.06% |
Dividends & Yields
This stock pays an annual dividend of 0.23, which amounts to a dividend yield of 0.97%.
| Dividend Per Share | 0.23 |
| Dividend Yield | 0.97% |
| Dividend Growth (YoY) | 90.43% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 26.10% |
| Buyback Yield | -2.78% |
| Shareholder Yield | -1.81% |
| Earnings Yield | 4.00% |
| FCF Yield | 2.48% |
Stock Splits
The last stock split was on May 24, 2024. It was a forward split with a ratio of 1.4.
| Last Split Date | May 24, 2024 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Hunan Jiudian Pharmaceutical has an Altman Z-Score of 9.48.
| Altman Z-Score | 9.48 |
| Piotroski F-Score | n/a |